美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

減肥藥

1,476.70

-15.4670-1.04%

漲家數：3

跌家數：4

平家數：- -

市盈率：- -

高：1,485.06

開：1,483.83

低：1,470.83

收：1,492.17

資料載入中...

總覽新聞資訊

禮來下調美國市場減肥藥價格，中國市場是否跟進

FDA官員加入輝瑞擔任高管，職業凱旋門？

Summit“滯銷”

AI獲醫藥巨頭認可！諾和諾德：AI終於足夠可靠，可以生成敏感文件

华尔街见闻

定價高達350萬美元的基因療法，上市一年未有銷售！輝瑞宣佈撤退

中国制药网

市場風雲突變！誰能穩坐“減肥藥王”寶座？

Ofweek光电信息网

康方生物依沃西攜手輝瑞ADC，國際化佈局提速

【歐股“十一羅漢”｜阿斯麥收跌2.2%，Hims減肥藥業務前景提振諾和諾德收漲約2.8%】週二，阿斯麥控股荷蘭阿姆斯特丹股價收跌2.20%，報697.80歐元。諾和諾德哥本哈根股價收漲2.78%，報657.00，美國平價減肥藥供應商Hims & Hers Health停售某些減肥藥。諾華製藥與葛蘭素史克至多漲2.35%，雀巢和阿斯利康至多漲1.41%，賽諾菲和羅氏製藥至多漲行0.7%，歐萊雅收平，德國思愛普Sap則收跌0.69%，LVMH集團跌1.14%。

Altimmune, Inc.盤中異動股價大跌5.07%報5.80美元

Viking Therapeutics, Inc.盤中異動大幅下跌5.00%

美股異動｜禮來漲超2.7% 推出10毫克劑量的小瓶裝Zepbound

港股那点事

諾和諾德盤中異動快速上漲3.04%

BUZZ-禮來公司收購 Organovo FXR 項目，Organovo 公司業績上升

禮來以折扣價提供瓶裝減肥藥以應對競爭

禮來美股盤前漲逾2%

每日经济新闻

BUZZ-禮來推出大劑量瓶裝減肥藥，股價上漲

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK4599/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4599"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","market":"US","secType":"PLATE","nameCN":"減肥藥","latestPrice":1476.7062,"timestamp":1741279694572,"preClose":1492.1732,"halted":0,"volume":18079690,"delay":0,"changeRate":-0.010365,"change":-15.467041,"pbRate":11.780703,"amount":1796293890.054696,"amplitude":0.00954,"prevYearClose":1305.0607,"fiveDayClose":1460.4895,"twentyDayClose":1394.0055,"turnoverRate":0.001713,"marketCap":1588061218080,"floatMarketCap":1475159021152,"peRate":41.703544},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","high":1485.0612,"amplitude":0.00954,"preClose":1492.1732,"low":1470.8256,"pbRate":"11.780703","latestPrice":1476.703,"volume":18078053,"delay":0,"open":1483.8325,"prevYearClose":1305.0607,"prevWeekClose":1482.1702,"prevMonthClose":1482.1702,"prevQuarterClose":1305.0607,"fiveDayClose":1460.4895,"twentyDayClose":1394.0055,"sixtyDayClose":1438.0239,"secType":"PLATE","market":"US","turnoverRate":0.001713,"peRate":41.703544,"marketCap":1588061218080,"floatMarketCap":1475159021152,"timestamp":1741279693519,"nameCN":"減肥藥"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4599\",,,,undefined,":{"bkCode":"BK4599","up":3,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4599\",pageSize:16,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514887118","title":"禮來下調美國市場減肥藥價格，中國市場是否跟進","url":"https://stock-news.laohu8.com/highlight/detail?id=2514887118","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514887118?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 18:07","pubTimestamp":1740564440,"startTime":"0","endTime":"0","summary":"当地时间2月25日，礼来美国市场宣布，下调减肥药Zepbound小瓶装的价格。公开资料显示，此次降价后，这两个剂量的药物月费用均减少50美元。替尔泊肽已进入中国市场销售。今年1月2日，礼来中国宣布穆峰达正式在中国上市，同时覆盖降糖以及减肥两项适应证。在全球市场，礼来的替尔泊肽直面与诺和诺德的司美格鲁肽竞争，后者属于GLP-1R单靶点药物，但上市时间更早。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226180819abddaa51&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226180819abddaa51&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LLY","LU1983299246.USD","SG9999013999.USD","LU0079474960.USD","IE00B4R5TH58.HKD","LU2491050071.SGD","LU1093756168.USD","LU1868836757.USD","SG9999014880.SGD","LU1551013425.SGD","LU0354030438.USD","LU1267930730.SGD","IE00BJJMRZ35.SGD","LU0672654240.SGD","LU0882574055.USD","LU2324357040.USD","BK4599","LU0058720904.USD","LU2089984988.USD","SGXZ81514606.USD","LU1720051108.HKD","LU0471298694.HKD","LU0354030511.USD","LU1868836591.USD","YINN","LU1064131342.USD","LU1868837300.USD","SGXZ31699556.SGD","LU0061475181.USD","LU1868836914.USD","BK4581","LU0943347566.SGD","LU2264538146.SGD","LU2237443622.USD","LU2211815571.USD","SG9999014914.USD","LU2491050154.USD","SG9999018865.SGD","LU0417517546.SGD","LU1280957306.USD","LU0096364046.USD","SG9999014898.SGD","LU0823416689.USD","LU0106261372.USD","LU0238689110.USD","IE00B1BXHZ80.USD","LU2360106947.USD","LU1989771016.USD","SG9999018857.SGD","LU0689472784.USD"],"gpt_icon":1},{"id":"2514835871","title":"FDA官員加入輝瑞擔任高管，職業凱旋門？","url":"https://stock-news.laohu8.com/highlight/detail?id=2514835871","media":"医药财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514835871?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 15:43","pubTimestamp":1740555811,"startTime":"0","endTime":"0","summary":"据悉，Patrizia Cavazzoni于今年1月离职FDA，她将领导辉瑞集团的监管、安全和医疗业务。然而，Patrizia Cavazzoni加入辉瑞担任首席医疗官的事件，可能引发多方面的讨论和影响，需从以下角度分析：1.职业旋转门的争议潜在利益冲突：Cavazzoni从监管机构转至药企，可能引发对其利用FDA内部经验或人脉的质疑。公众可能担忧监管机构与企业间的“旋转门”现象削弱监管独立性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226190634a254c14f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226190634a254c14f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BBT3K403.USD","SG9999011175.SGD","BK4534","LU0225771236.USD","LU0289739699.SGD","PFE","BK4592","LU0306807586.USD","LU0306806265.USD","BK4599","LU0456855351.SGD","LU1066053197.SGD","BK4007","LU0234572021.USD","SG9999001176.USD","BK4588","SG9999002232.USD","LU1883839398.USD","SG9999001176.SGD","LU0170899867.USD","LU1894683348.USD","LU0122379950.USD","SG9999003800.SGD","LU0321505439.SGD","LU1057294990.SGD","IE00B19Z3B42.SGD","BK4550","BK4585","BK4568","IE00BLSP4239.USD","IE00B19Z3581.USD","LU0321505868.SGD","SG9999002224.SGD","LU0058720904.USD","IE00BLSP4452.SGD","LU0868494617.USD","SGXZ57979304.SGD","LU1023059063.AUD","LU1066051498.USD","LU0985481810.HKD","SG9999013999.USD","LU0225284248.USD","LU1894683264.USD","BK4533","BK4581","IE000M9KFDE8.USD","IE0002270589.USD"],"gpt_icon":1},{"id":"2514005348","title":"Summit“滯銷”","url":"https://stock-news.laohu8.com/highlight/detail?id=2514005348","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514005348?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 14:29","pubTimestamp":1740551372,"startTime":"0","endTime":"0","summary":"Summit的潜在买家，范围持续缩窄。2月24日，Summit宣布与辉瑞达成临床试验合作，共同评估PD-1/VEGF双抗AK112与辉瑞多个ADC联合用于多种实体瘤的疗效和安全性。根据合作条款，辉瑞将负责临床试验的开展和费用，Summit则供药，双方各自保留其产品的相关权利。在乐观者看来，这是辉瑞盯上了Summit。合作消息发布后，Summit股价应声大跌14.83%。当然，Summit“滞销”并非说AK112前景不好。Summit股价大跌，但康方生物今日股价涨幅近5%。此次与Summit牵手，“暧昧”程度不用多说。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/251700","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU0321505439.SGD","LU1585245621.USD","IE000M9KFDE8.USD","SG9999014542.SGD","LU0203345920.USD","LU0321505868.SGD","LU0289739699.SGD","LU0965509283.SGD","LU1989772840.SGD","LU2023250504.SGD","LU0985481810.HKD","LU1989772923.USD","LU0058720904.USD","SG9999015341.SGD","BK4533","LU1023059063.AUD","LU1093756168.USD","IE00BJJMRZ35.SGD","LU1699723380.USD","LU1989771016.USD","SG9999015358.SGD","LU1934455194.USD","LU0234572021.USD","SG9999001176.SGD","BK4588","LU2468319806.SGD","LU0211331839.USD","IE0009355771.USD","IE00B2B36J28.USD","LU1894683264.USD","IE00BBT3K403.USD","LU0320765489.SGD","IE00BSNM7G36.USD","BK4599","SG9999002224.SGD","SG9999001440.SGD","SG9999013999.USD","LU0965508806.USD","BK4585","BK4550","LU0265550359.USD","IE00B19Z3B42.SGD","LU1571399168.USD","LU1929549753.HKD","LU1061106388.HKD","IE00BN8TJ469.HKD","LU1066051225.USD","LU0238689110.USD"],"gpt_icon":1},{"id":"2514794330","title":"AI獲醫藥巨頭認可！諾和諾德：AI終於足夠可靠，可以生成敏感文件","url":"https://stock-news.laohu8.com/highlight/detail?id=2514794330","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514794330?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 11:43","pubTimestamp":1740541419,"startTime":"0","endTime":"0","summary":"目前，诺和诺德已经开始使用Claude起草临床研究报告，每份可长达数百页。相关负责人透露，AI工具的使用极大缩短了文件起草时间，从约15周减少到不到10分钟，且公司每年在Claude上的支出不到一名撰稿人的薪资。","market":"us","thumbnail":"https://static.tigerbbs.com/683468f057f519a90154e567b0fb2faf","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/683468f057f519a90154e567b0fb2faf"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3741894","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3741894","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"AI获医药巨头认可！诺和诺德：AI终于足够可靠，可以生成敏感文件","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["BK4588","LU1093756168.USD","BK4532","LU0154236417.USD","NVO","BK1574","BK4007","BK4585","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK1161","BK1515","BK4599","LU1093756325.SGD"],"gpt_icon":1},{"id":"2514075929","title":"定價高達350萬美元的基因療法，上市一年未有銷售！輝瑞宣佈撤退","url":"https://stock-news.laohu8.com/highlight/detail?id=2514075929","media":"中国制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514075929?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 10:40","pubTimestamp":1740537620,"startTime":"0","endTime":"0","summary":"近日，制药头部辉瑞做出一项重大决策，宣布停止 B 型血友病基因疗法 Beqvez 的研发和商业化进程。值得一提的是Beqvez 在 2024 年 4 月才刚刚获得 FDA 批准上市，定价高达 350 万美元，但是一年时间过去，辉瑞便决定终止了该药物的开发和商业化。这一系列动作表明，辉瑞正在逐步退出细胞基因疗法领域。Biomarin 公司的 A 型血友病基因疗法 RocTavian 同样销售缓慢，2023 年 6 月获 FDA 批准上市，定价 2900 万美元，2024 年销售额仅 2600 万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226110458abdd316c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226110458abdd316c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B19Z3581.USD","IE00BLSP4239.USD","SG9999002224.SGD","LU0170899867.USD","BK4588","LU1894683264.USD","LU1023059063.AUD","SG9999011175.SGD","LU1883839398.USD","BK4533","LU0456855351.SGD","LU0225284248.USD","LU0234572021.USD","LU1066053197.SGD","IE00BLSP4452.SGD","LU0321505439.SGD","SG9999001176.SGD","BK4592","IE0002270589.USD","LU1066051498.USD","LU1894683348.USD","SG9999002232.USD","SG9999003800.SGD","BK4007","BK4585","LU1057294990.SGD","LU0225771236.USD","LU0321505868.SGD","PFE","BK4599","BK4534","SG9999013999.USD","BK4568","IE00B19Z3B42.SGD","LU0868494617.USD","LU0058720904.USD","IE00BBT3K403.USD","LU0985481810.HKD","BK4550","LU0306807586.USD","SGXZ57979304.SGD","LU0289739699.SGD","LU0306806265.USD","LU0122379950.USD","SG9999001176.USD","IE000M9KFDE8.USD","BK4581"],"gpt_icon":1},{"id":"2514020435","title":"市場風雲突變！ 誰能穩坐“減肥藥王”寶座？","url":"https://stock-news.laohu8.com/highlight/detail?id=2514020435","media":"Ofweek光电信息网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514020435?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 09:54","pubTimestamp":1740534840,"startTime":"0","endTime":"0","summary":"如今，市场悄然发生变化。同时，礼来的减肥药在国内开售，区域性的销售法规出台。今年2月，诺和诺德直接将亨利医药及黄振华告上法庭，指控其涉嫌欺诈。至于交易完成后的转移资产行为，目前黄振华方面尚未出面解释。目前，诺和诺德已向新加坡法院申请，向黄振华及其企业合计索赔8.3亿美元，并要求全球范围内冻结相关资产。目前，法院仍未最终裁定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022609562996308237&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022609562996308237&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","NVO","BK4588","LU1093756325.SGD","LU0154236417.USD","BK4007","LU1093756168.USD","BK4532","BK4599","BK4585","IE00BKVL7J92.USD"],"gpt_icon":1},{"id":"2514020285","title":"康方生物依沃西攜手輝瑞ADC，國際化佈局提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2514020285","media":"国泰君安","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514020285?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 09:15","pubTimestamp":1740532557,"startTime":"0","endTime":"0","summary":"2月24日，公司海外合作伙伴Summit Therapeutics宣布与辉瑞达成临床试验合作，有望深入挖掘依沃西联合辉瑞多款vedotin系列ADCs药物联合疗法在多种实体瘤中的巨大潜力。辉瑞为全球ADC领域头部玩家，有望提供丰富产品组合。多项临床布局推动下，依沃西有望在肺癌领域实现全线布局，与ADC的联合给药有望在长期进一步带来治疗模式的突破。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226093052a2541cfb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226093052a2541cfb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1883839398.USD","SG9999013999.USD","LU0868494617.USD","LU1057294990.SGD","IE00BLSP4452.SGD","LU0306807586.USD","BK4231","SG9999011175.SGD","LU0321505868.SGD","BK4592","BK4533","BK4581","IE00B19Z3581.USD","LU0058720904.USD","LU0225284248.USD","ADC","LU0170899867.USD","LU0306806265.USD","IE000M9KFDE8.USD","BK4568","LU1023059063.AUD","SG9999001176.USD","LU1894683348.USD","IE0002270589.USD","BK4550","IE00B19Z3B42.SGD","BK4080","SG9999001176.SGD","BK4585","LU0321505439.SGD","LU0985481810.HKD","BK4534","SGXZ57979304.SGD","PFE","LU0234572021.USD","BK4599","LU1066051498.USD","LU0122379950.USD","IE00BLSP4239.USD","SG9999003800.SGD","BK4007","IE00BBT3K403.USD","LU0225771236.USD","LU0289739699.SGD","BK4588","SG9999002232.USD","LU0456855351.SGD","LU1066053197.SGD","LU1894683264.USD","SG9999002224.SGD"],"gpt_icon":1},{"id":"2514950017","title":"【歐股“十一羅漢”｜阿斯麥收跌2.2%，Hims減肥藥業務前景提振諾和諾德收漲約2.8%】 週二，阿斯麥控股荷蘭阿姆斯特丹股價收跌2.20%，報697.80歐元。諾和諾德哥本哈根股價收漲2.78%，報657.00，美國平價減肥藥供應商Hims & Hers Health停售某些減肥藥。諾華製藥與葛蘭素史克至多漲2.35%，雀巢和阿斯利康至多漲1.41%，賽諾菲和羅氏製藥至多漲行0.7%，歐萊雅收平，德國思愛普Sap則收跌0.69%，LVMH集團跌1.14%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514950017","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514950017?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 01:54","pubTimestamp":1740506070,"startTime":"0","endTime":"0","summary":"周二，阿斯麦控股荷兰阿姆斯特丹股价收跌2.20%，报697.80欧元。诺和诺德哥本哈根股价收涨2.78%，报657.00，美国平价减肥药供应商Hims & Hers Health停售某些减肥药。诺华制药与葛兰素史克至多涨2.35%，雀巢和阿斯利康至多涨1.41%，赛诺菲和罗氏制药至多涨行0.7%，欧莱雅收平，德国思爱普Sap则收跌0.69%，LVMH集团跌1.14%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/26015448386051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4543","BK4212","LU0823434583.USD","BK4578","LU0109394709.USD","LU0211331839.USD","GSK","BK4183","IE00BJT1NW94.SGD","NVS","BK4147","LU0823434740.USD","ASML","LU2236285917.USD","IE0002141913.USD","NSRGY","IE00BFTCPJ56.SGD","LU2456880835.USD","LU1093756325.SGD","LRLCY","BK4007","IE00BD6J9T35.USD","LU0320765992.SGD","IE00BZ1G4Q59.USD","IE00B4R5TH58.HKD","LU2462157665.USD","LU0097036916.USD","BK4532","03165","LU1829250122.USD","BK4568","NVO","LU0889565916.HKD","IE0004445239.USD","BK1574","LU1093756168.USD","LU2063271972.USD","AZN","BK4585","LU0154236417.USD","01477","BK4599","LU2417539215.USD","IE00B2B36J28.USD","GSK.UK","IE00BKVL7J92.USD","BK1191","IE0009355771.USD","LU1734074674.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2514148800","title":"Altimmune, Inc.盤中異動 股價大跌5.07%報5.80美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514148800","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514148800?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 00:32","pubTimestamp":1740501166,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时32分，Altimmune, Inc.股票出现异动，股价急速下跌5.07%。截至发稿，该股报5.80美元/股，成交量100.272万股，换手率1.41%，振幅6.87%。Altimmune, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Organovo Holdings, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Silexion Therapeutics Corp涨幅较大，Organovo Holdings, Inc.、Gt Biopharma, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为1390.94%、1116.23%、913.93%，振幅较大的相关个股有Organovo Holdings, Inc.、Silexion Therapeutics Corp、Abpro Holdings Inc C/Wts 12/11/2029 ，振幅分别为224.93%、87.83%、66.67%。Altimmune, Inc.公司简介：Altimmune Inc 从事开发治疗肥胖症和肝病的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226003246abdc9ada&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226003246abdc9ada&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1878469433.USD","BK4599","ALT","BK4139"],"gpt_icon":0},{"id":"2514015658","title":"Viking Therapeutics, Inc.盤中異動 大幅下跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514015658","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514015658?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 23:27","pubTimestamp":1740497261,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日23时27分，Viking Therapeutics, Inc.股票出现波动，股价急速下跌5.00%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.79%。其相关个股中，Organovo Holdings, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Cingulate Inc C/Wts 10/12/2026 涨幅较大，Gt Biopharma, Inc.、Organovo Holdings, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为1064.18%、913.07%、592.70%，振幅较大的相关个股有Organovo Holdings, Inc.、Adial Pharmaceuticals, Inc、Silexion Therapeutics Corp，振幅分别为121.95%、64.05%、61.16%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225232741abdc8ca0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225232741abdc8ca0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","BK4599","BK4139","VKTX","LENZ"],"gpt_icon":0},{"id":"2514018334","title":"美股異動｜禮來漲超2.7% 推出10毫克劑量的小瓶裝Zepbound","url":"https://stock-news.laohu8.com/highlight/detail?id=2514018334","media":"港股那点事","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514018334?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 22:42","pubTimestamp":1740494520,"startTime":"0","endTime":"0","summary":"格隆汇2月25日｜礼来(LLY.US)涨超2.7%，报905.4美元。消息面上，礼来公司宣布，畅销减肥药Zepbound 2.5毫克和5毫克规格的小瓶装产品月度价格将分别降至349美元和499美元，较此前降低约50美元。另外，礼来还推出了10毫克剂量的小瓶装Zepbound，月度价格为499美元。礼来公司高管表示，自Zepbound上市以来，已有超过10%的患者开始服用小剂量Zepbound。(格隆汇)\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2025-02-25/doc-inemtimv4271576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LLY","LU0079474960.USD","IE00B4R5TH58.HKD","LU2468319806.SGD","LU2491050071.SGD","LU1093756168.USD","BK4533","LU0354030438.USD","LU0672654240.SGD","SG9999001176.USD","BK4599","IE00BJLML261.HKD","LU0058720904.USD","LU0456855351.SGD","LU1057294990.SGD","BK4534","BK4007","SG9999014906.USD","LU0354030511.USD","LU0094547139.USD","IE00BJT1NW94.SGD","LU0256863902.USD","LU1868837300.USD","LU0061475181.USD","LU0114720955.EUR","LU2237443978.SGD","LU1868836914.USD","LU0640476718.USD","LU1814569148.SGD","LU0203201768.USD","IE0004445239.USD","LU2237443622.USD","LU2211815571.USD","LU2461242641.AUD","LU0820561818.USD","LU2491050154.USD","SGXZ99366536.SGD","LU0109391861.USD","LU1069344957.HKD","IE00B1BXHZ80.USD","LU1974910355.USD","LU1061106388.HKD","LU1623119135.USD","LU2023250504.SGD","LU2360106947.USD","SG9999015952.SGD","LU2237438978.USD","SG9999018857.SGD","LU2112291526.USD","LU1127390331.HKD"],"gpt_icon":0},{"id":"2514090106","title":"諾和諾德盤中異動 快速上漲3.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514090106","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514090106?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 22:34","pubTimestamp":1740494093,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时34分，诺和诺德股票出现异动，股价大幅拉升3.04%。诺和诺德股票所在的制药行业中，整体涨幅为1.62%。诺和诺德还有一个生物制药部门，专门从事血友病和其他疾病的蛋白质疗法。时间回溯至2023年10月，诺和诺德以13亿美元的价格收购了KBP的核心在研药物Ocedurenone。为保障索赔权益，诺和诺德于2025年2月14日获得新加坡法院批准的全球资产冻结令，覆盖KBP在新加坡星展银行的2.18亿美元存款，以及黄振华价值700万美元的房产。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223453962ff342&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223453962ff342&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LU1093756168.USD","IE00BKVL7J92.USD","BK4599","IE00BZ1G4Q59.USD","NVO","BK4585","BK4532","LU0154236417.USD","BK4588","LU1093756325.SGD"],"gpt_icon":1},{"id":"2514091019","title":"BUZZ-禮來公司收購 Organovo FXR 項目，Organovo 公司業績上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2514091019","media":"路透中文","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514091019?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 21:42","pubTimestamp":1740490950,"startTime":"0","endTime":"0","summary":"2月25日 -  ** Organovo Holdings ONVO.O的股价盘前上涨两倍多，达到1.35美元 ** ONVO称 ，它正在向礼来LLY.N出售其FXR项目，包括主要资产FXR314。** LLY 将获得 Organovo FXR 项目的所有商业和知识产权，用于全球开发。** ONVO 表示，收购将使礼来公司能够从中期阶段开始进一步开发 FXR314 ** 2024 年，ONVO 下跌约 68(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nL3S3PG18U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1280957306.USD","BK4139","LU2237443978.SGD","LU0354030511.USD","LU0708995401.HKD","SG9999015952.SGD","SG9999017495.SGD","LU1720051108.HKD","LU0203201768.USD","LU0096364046.USD","LU1267930730.SGD","LU2361045086.USD","ONVO","LLY","LU2357305700.SGD","LU0320765059.SGD","BK4599","LU2023250504.SGD","LU1868837300.USD","SG9999018865.SGD","LU1023059063.AUD","LU0820561818.USD","BK4581","LU1868836591.USD","SG9999001176.SGD","SG9999018857.SGD","LU1983299246.USD","IE00BJT1NW94.SGD","LU2491049909.HKD","LU0417517546.SGD","SG9999001176.USD","LU1868836757.USD","SG9999015986.USD","LU1069344957.HKD","LU1035775433.USD","SG9999013999.USD","LU0882574055.USD","LU0471298694.HKD","IE00B2B36J28.USD","LU2602419157.SGD","LU2361044949.HKD","LU2360106947.USD","LU0256863902.USD","LU2324357040.USD","LU1093756325.SGD","IE00BFTCPJ56.SGD","BK4585","LU1551013425.SGD","LU2237443382.USD","SGXZ51526630.SGD"],"gpt_icon":1},{"id":"2514096860","title":"禮來以折扣價提供瓶裝減肥藥以應對競爭","url":"https://stock-news.laohu8.com/highlight/detail?id=2514096860","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514096860?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 20:49","pubTimestamp":1740487772,"startTime":"0","endTime":"0","summary":"更新版 3-礼来以折扣价提供瓶装减肥药以应对竞争新定价旨在通过礼来直销吸引现金支付客户Hims & Hers警告称可能停止销售诺和诺德复方减肥药远程医疗公司股价下跌第 2-10 段增加了有关复方药物的细节和 Noom 首席执行官的评论Patrick  Wingrove/Sriparna  Roy. 路透社2月25日 - 礼来LLY.N周二表示，它将其减肥药Zepbound的小瓶售价下调了50美元或更多，并扩大了网上销售的剂量范围，以试图抵御来自复合药房和竞争对手诺和诺德NOVOb.CO的竞争。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nL3S3PG150:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0256863811.USD","LU1057294990.SGD","IE00BK4W5M84.HKD","IE00BJLML261.HKD","SG9999015945.SGD","SGXZ81514606.USD","SG9999018857.SGD","LU0471298777.SGD","LU0385154629.USD","LU1035775433.USD","LU2023250504.SGD","SG9999015986.USD","LU1804176565.USD","LU1868836591.USD","SGXZ51526630.SGD","LU1069344957.HKD","SGXZ31699556.SGD","LU1093756168.USD","LU2461242641.AUD","LU1861558580.USD","LU1712237335.SGD","LFMD","BK4588","LU0097036916.USD","LU0672654240.SGD","LU2063271972.USD","LU1127390331.HKD","LU0122379950.USD","LU2491049909.HKD","IE00B4R5TH58.HKD","LU0061475181.USD","LU2361044865.SGD","BK4567","BK4533","BK4599","LU2237443465.HKD","LU1868837136.USD","IE00BFTCPJ56.SGD","BK4007","SG9999001176.SGD","LLY","SG9999014914.USD","LU1064131342.USD","LU0466842654.USD","LU2360106947.USD","LU0456855351.SGD","LU0198837287.USD","LU2361045086.USD"],"gpt_icon":1},{"id":"2514096548","title":"禮來美股盤前漲逾2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514096548","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514096548?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 20:23","pubTimestamp":1740486220,"startTime":"0","endTime":"0","summary":"礼来美股盘前涨逾2%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202502253329223960.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502253329223960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1868836757.USD","LU1712237335.SGD","SGXZ57979304.SGD","LU1035775433.USD","LU1804176565.USD","LU0122379950.USD","LU1093756168.USD","LU2324357040.USD","LU1974910355.USD","LU2237443382.USD","LU1868837300.USD","LU0198837287.USD","LU0943347566.SGD","IE00BJLML261.HKD","IE00BJT1NW94.SGD","LU0471298694.HKD","LU0094547139.USD","LU0417517546.SGD","LU2106854487.HKD","IE00BFTCPJ56.SGD","LLY","LU0289739699.SGD","LU2237443622.USD","LU2211815571.USD","LU2491050154.USD","SG9999013999.USD","BK4007","LU1720051108.HKD","LU1093756325.SGD","LU2264538146.SGD","LU0109391861.USD","LU1868836591.USD","BK4599","LU0354030511.USD","GB00BDT5M118.USD","LU0882574055.USD","LU0096364046.USD","LU1551013342.USD","LU2361044949.HKD","BK4585","IE00BK4W5L77.USD","LU0689472784.USD","LU2063271972.USD","LU0820561818.USD","LU0456855351.SGD","LU2265009873.SGD","LU0114720955.EUR","LU0820561909.HKD","LU1366192091.USD","LU2237443895.HKD"],"gpt_icon":0},{"id":"2514093433","title":"BUZZ-禮來推出大劑量瓶裝減肥藥，股價上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2514093433","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514093433?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 20:20","pubTimestamp":1740486048,"startTime":"0","endTime":"0","summary":"** 称已将低剂量小瓶药品一个月的供应量降价约 50 美元  ** LLY 在过去 12 个月中上涨了 14.5(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"83ee8187a7c6b491c0a55b1ec36d2adb","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nL3S3PG12W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106261372.USD","LU1064131342.USD","LU1035775433.USD","SG9999015952.SGD","LU2237443622.USD","SG9999001176.USD","SG9999017495.SGD","IE00BJLML261.HKD","LU2264538146.SGD","LU2461242641.AUD","SG9999014898.SGD","LU0943347566.SGD","LU2491050154.USD","LU0289739699.SGD","SG9999013999.USD","LU0640476718.USD","LU1291159041.SGD","SGXZ57979304.SGD","LU2112291526.USD","LU2237438978.USD","LU2211815571.USD","BK4585","LU0456855351.SGD","LU1868837300.USD","LU0882574055.USD","LU1093756325.SGD","LU0466842654.USD","LU1069344957.HKD","LU2237443549.SGD","LU0689472784.USD","LU2360106947.USD","LU2361044865.SGD","LU0198837287.USD","LU1551013425.SGD","LLY","LU2106854487.HKD","BK4516","IE00BK4W5M84.HKD","SGXZ31699556.SGD","GB00BDT5M118.USD","IE00B4R5TH58.HKD","SG9999018865.SGD","SG9999015978.USD","LU2063271972.USD","IE00BJJMRZ35.SGD","LU0471298694.HKD","LU1804176565.USD","LU1023059063.AUD","BK4599","LU1974910355.USD"],"gpt_icon":0}],"pageSize":16,"totalPage":7,"pageCount":4,"totalSize":111}]}}